Morgan Stanley has trimmed SINOPHARM's (01099) profit projections for 2025-2030 by 1%-6%, citing reduced sales forecasts within its medical apparatus and pharmaceutical distribution divisions. Consequently, the investment bank adjusted its price target downward from HK$23 to HK$22.5 while maintaining an "Overweight" rating on the stock.
The revised outlook reflects anticipated headwinds in two core business segments, though analysts continue to endorse strategic positioning for long-term growth potential. This recalibration aligns with evolving market dynamics in China's healthcare distribution landscape, where SINOPHARM maintains significant market presence.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。